微信公众号
证券之星APP
| 报告期 | 销售毛利率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 29.4% | 27.78% | -3.23% | 117/159 | -1.59% | 海创药业 | 99.57% | 行业排名> |
| 2025-06-30 | 30.38% | 21.07% | 4.92% | 118/159 | 15.28% | 海创药业 | 99.52% | 行业排名> |
| 2025-03-31 | 28.95% | 76.84% | 54.51% | 117/159 | 32.3% | 艾力斯 | 96.74% | 行业排名> |
| 2024-12-31 | 18.74% | -31.63% | -18.55% | 141/159 | 51.78% | 首药控股 | 98.96% | 行业排名> |
| 2024-09-30 | 23.01% | -20.2% | -8.31% | 134/159 | 22.81% | 迪哲医药 | 97.73% | 行业排名> |
| 2024-06-30 | 25.09% | -18.55% | 53.26% | 130/159 | 33.25% | 百利天恒 | 97.99% | 行业排名> |
| 2024-03-31 | 16.37% | -10.46% | -40.26% | 138/159 | 51.56% | 百利天恒 | 98.92% | 行业排名> |
| 2023-12-31 | 27.4% | -25.93% | -4.94% | 125/159 | 51.39% | 迈威生物 | 98.93% | 行业排名> |
| 2023-09-30 | 28.83% | -16.92% | -6.41% | 123/159 | 32.56% | 迈威生物 | 99.59% | 行业排名> |
| 2023-06-30 | 30.81% | -6.82% | 68.48% | 119/159 | 38.45% | 迈威生物 | 99.8% | 行业排名> |
| 2023-03-31 | 18.28% | -43.33% | -50.58% | 136/159 | 52.78% | 迈威生物 | 99.46% | 行业排名> |
| 2022-12-31 | 37% | -3.52% | 6.62% | 110/159 | 53.66% | 迈威生物 | 99.75% | 行业排名> |
| 2022-09-30 | 34.7% | -15.67% | 4.96% | 107/159 | 6.2% | 迈威生物 | 99.67% | 行业排名> |
| 2022-06-30 | 33.06% | -12.19% | 2.47% | 112/159 | 21.37% | 迈威生物 | 99.44% | 行业排名> |
| 2022-03-31 | 32.26% | -3.34% | -15.87% | 107/159 | 54.28% | 迈威生物 | 98.57% | 行业排名> |
| 2021-12-31 | 38.35% | -5.63% | -6.81% | 108/159 | 55.1% | 首药控股 | 99.93% | 行业排名> |
| 2021-09-30 | 41.15% | -0.31% | 9.29% | 88/159 | 46.78% | 艾力斯 | 99.41% | 行业排名> |
| 2021-06-30 | 37.65% | 1.25% | 12.81% | 107/159 | 47.23% | 艾力斯 | 98.7% | 行业排名> |
| 2021-03-31 | 33.38% | 16.11% | -17.86% | 99/159 | 53.99% | 艾力斯 | 99.4% | 行业排名> |
| 2020-12-31 | 40.63% | -12.54% | -1.56% | 104/159 | -145.9% | 首药控股 | 99.94% | 行业排名> |
| 2020-09-30 | 41.28% | -18.48% | 11.01% | 87/159 | 56.36% | 泽璟制药 | 99.96% | 行业排名> |
| 2020-06-30 | 37.19% | -28.01% | 29.36% | 102/159 | 54.11% | 微芯生物 | 95.14% | 行业排名> |
| 2020-03-31 | 28.75% | -41.55% | -38.13% | 99/159 | 55.23% | 多瑞医药 | 95.59% | 行业排名> |
| 2019-12-31 | 46.46% | -18.23% | -8.25% | 86/159 | -1222.98% | 微芯生物 | 95.81% | 行业排名> |
| 2019-09-30 | 50.64% | -12.19% | -1.97% | 63/159 | 55.21% | 微芯生物 | 96.09% | 行业排名> |
| 2019-06-30 | 51.66% | -20.46% | 5.03% | 61/159 | 55.21% | 微芯生物 | 96.11% | 行业排名> |
| 2019-03-31 | 49.18% | -28.97% | -13.45% | 58/159 | 51.05% | 微芯生物 | 95.5% | 行业排名> |
| 2018-12-31 | 56.82% | 11.65% | -1.47% | 62/159 | -208.09% | 微芯生物 | 96.27% | 行业排名> |
| 2018-09-30 | 57.67% | 21.29% | -11.2% | 47/159 | 53.97% | 贝达药业 | 95.47% | 行业排名> |
| 2018-06-30 | 64.94% | 32.49% | -6.21% | 29/159 | 53.39% | 贝达药业 | 95.51% | 行业排名> |
| 2018-03-31 | 69.24% | 43.18% | 36.05% | 22/159 | 53.9% | 贝达药业 | 95.54% | 行业排名> |
| 2017-12-31 | 50.89% | -2.48% | 7.04% | 64/159 | 52.32% | 贝达药业 | 95.74% | 行业排名> |
| 2017-09-30 | 47.54% | -0.83% | -3% | 50/159 | 49% | 退市金泰 | 96.19% | 行业排名> |
| 2017-06-30 | 49.02% | 4.08% | 1.36% | 50/159 | 47.74% | 贝达药业 | 95.81% | 行业排名> |
| 2017-03-31 | 48.36% | 7.26% | -7.34% | 41/159 | 46.55% | 退市金泰 | 95.93% | 行业排名> |
| 2016-12-31 | 52.19% | 61.52% | 8.85% | 44/159 | 48.19% | 贝达药业 | 95.58% | 行业排名> |
| 2016-09-30 | 47.94% | 81.14% | 1.8% | 33/159 | 45.76% | 贝达药业 | 95.89% | 行业排名> |
| 2016-06-30 | 47.1% | 89.06% | 4.46% | 40/159 | 45.89% | 微芯生物 | 97.46% | 行业排名> |
| 2016-03-31 | 45.09% | 167.37% | 39.54% | 33/159 | 43.5% | 贝达药业 | 97.01% | 行业排名> |
| 2015-12-31 | 32.31% | 246.31% | 22.08% | 76/159 | 45.97% | 贝达药业 | 97.02% | 行业排名> |
| 2015-09-30 | 26.47% | 189.45% | 6.25% | 61/159 | 44.69% | 舒泰神 | 94.38% | 行业排名> |
| 2015-06-30 | 24.91% | 88.99% | 47.72% | 67/159 | 45% | 贝达药业 | 96.95% | 行业排名> |
| 2015-03-31 | 16.86% | 101.74% | 80.74% | 71/159 | 43.46% | 舒泰神 | 94.4% | 行业排名> |